BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Logo poskytovatele

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Fakultu informatiky. Oficiální stránka publikace je na webu muni.cz.

Autoři

ŠIMARA Pavel PETERKOVÁ Martina STEJSKAL Stanislav POTĚŠILOVÁ Michaela KRONTORÁD KOUTNÁ Irena RÁČIL Zdeněk RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana MAYER Jiří

Rok publikování 2012
Druh Článek v odborném periodiku
Časopis / Zdroj Leukemia & lymphoma
Fakulta / Pracoviště MU

Fakulta informatiky

Citace
www http://www.ncbi.nlm.nih.gov/pubmed/22233112
Doi http://dx.doi.org/10.3109/10428194.2012.656104
Obor Onkologie a hematologie
Klíčová slova p-CrkL; chronic myeloid leukemia; imatinib
Popis In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info